METHODS

Analytic Overview Treatment Strategies
Using a computer-based model of HIV disease, we examined the policy decision regarding when to initiate ART in South Africa. We considered 3 strategies for interim treatment until the results of the ART initiation trials are available: no treatment (for comparison purposes), initiate ART at a CD4 count less than 0.250 ϫ 10 9 cells/L (or severe opportunistic disease) (7) , and initiate ART at a CD4 count less than 0.350 ϫ 10 9 cells/L (or severe opportunistic disease). We initiated cotrimoxazole prophylaxis at a CD4 count less than 0.500 ϫ 10 9 cells/L in all strategies, in accordance with WHO recommendations (10) . We examined the effect of this decision over both short-term (5-year) and lifetime horizons. We emphasize that all of these strategies would involve acting optimally on the results of the trials once they are available in 5 years.
To report on cost-effectiveness, we adopted a modified societal perspective, considering only direct, HIV-associated use of medical resources. We reported all costs in 2006 U.S. dollars by using country-specific gross domestic product (GDP) deflators and the 2006 mean exchange rate between the South African rand and the U.S. dollar (6.8 rand ϭ 1 U.S. dollar) (11, 12) . We discounted all costs and life expectancies at 3% per year (13) . The WHO guidelines designate health interventions as cost-effective if the cost per quality-adjusted life-year is less than 3 times the country's per-capita GDP, and very cost-effective if the cost per quality-adjusted life-year is less than the country's per-capita GDP (14, 15) . Although our analysis computes cost-effectiveness ratios in terms of years of life saved (YLS) (rather than quality-adjusted life-years), these thresholds provide general guidance. As a reference point, we compared the results with South Africa's 2006 per-capita GDP (U.S. $5400) (11) .
Projections Over the Next 5 Years
We first examined the policy over the next 5 years to inform decisions regarding whether it would be best to consider therapy at a CD4 count threshold of 0.350 ϫ 10 9 cells/L rather than 0.250 ϫ 10 9 cells/L while waiting for the clinical trial results. We did this in 2 steps. First, we projected the number of South African patients who would require ART over the 5-year time horizon and their anticipated short-term clinical outcomes (defined as deaths and opportunistic diseases) and costs under alternative ART initiation scenarios. To do so, we used model-based methods, similar to those previously described (16) , to examine how many HIV-infected persons in South Africa would be eligible for ART at a CD4 count threshold of 0.350 ϫ 10 By combining data from the WHO and the President's Emergency Plan for AIDS Relief, we estimated the proportion of HIV-infected persons who were identified and linked to care in South Africa (Appendix 2, available at www.annals.org) (17, 18) . We estimated the effect if 10% (the proportion estimated to be receiving ART), 30% (the estimate of those receiving either ART or other, general President's Emergency Plan for AIDS Relief services), or 100% (as an upper bound) of patients were linked to care.
Finally, we assumed that a clinical trial will provide perfect information in 5 years about whether using an ART initiation threshold of 0.350 ϫ 10 9 cells/L is more efficacious than the current standard of care and developed a decision criterion under which it would be cost-effective (Ͻ3 ϫ GDP) to invoke a policy of initiation at a CD4 count threshold of 0.350 ϫ 10 9 cells/L now while awaiting clinical trial results. This criterion included a threshold value for the probability that the trials will demonstrate the superiority of starting ART at CD4 counts less than 0.350 ϫ 10 9 cells/L.
Developing a Decision Criterion
To develop a decision criterion for earlier ART initiation now, we examined 2 potential policy scenarios (ART initiation at CD4 counts Ͻ0.350 ϫ 10 9 cells/L vs. Ͻ0.250 ϫ 10 9 cells/L) over the next 5 years and their associated clinical and economic outcomes (Figure 1) . These outcomes excluded any long-term benefits, detriments, or
Context
Rapid control of HIV infection is especially important in resource-limited countries with high rates of opportunistic infections. Therapy initiation guidelines would be useful for South African physicians while awaiting the results of ongoing trials of different CD4 count thresholds for therapy initiation.
Contribution
The investigators used a computer simulation of HIV disease to perform a cost-effectiveness analysis of 3 options: no treatment and thresholds of 0.250 and 0.350 ϫ 10 9 cells/L. Compared with a threshold of 0.250 ϫ 10 9 cells/L, starting at 0.350 ϫ 10 9 cells/L was highly cost-effective, even when the probability that a trial would show its superiority was as low as 17%.
Implication
Earlier antiretroviral therapy will probably prove to be superior in South Africa.
-The Editors
Article When to Start Antiretroviral Therapy in Resource-Limited Settings costs potentially associated with either decision beyond the 5-year horizon. Although the calculated outcomes included ART-related toxicities, they also excluded any excess toxicity that might be associated with earlier ART beyond the 5-year horizon. If ART is initiated at a CD4 count less than 0.350 ϫ 10 9 cells/L, the trial may demonstrate in 5 years that a 0.350 ϫ 10 9 cells/L initiation threshold provides a benefit (probability P) or that it produces equivalent outcomes to a 0.250 ϫ 10 9 cells/L threshold (probability 1 Ϫ P). In the latter case, the associated costs of a 0.350 ϫ 10 9 cells/L initiation threshold include not only those of earlier initiation but also the HIV medical costs accrued because of the additional deaths ($536 each) and opportunistic diseases (ranging from $105 to $1006 each) anticipated with using a CD4 count threshold of 0.250 ϫ 10 9 cells/L compared with those anticipated with using 0.350 ϫ 10 9 cells/L (19) . If ART is initiated at a CD4 count less than 0.250 ϫ 10 9 cells/L over the next 5 years, clinical outcomes and costs would be those derived for the shortterm strategy of initiating ART at CD4 counts less than 0.250 ϫ 10 9 cells/L. Averaging out the simple tree in Figure 1 , we created the decision rule under which it would be economically efficient to set the initiation threshold at 0.350 ϫ 10 9 cells/L now. We defined this decision rule by examining alternative values for P and using the cost-effectiveness willingness-to-pay threshold of 3 times GDP ($16 200/YLS).
Lifetime Projections
After projecting 5-year outcomes, we then projected and compared the per-person life expectancy and mean lifetime HIV treatment costs for patients at CD4 count thresholds for ART initiation of 0.350 ϫ 10 9 cells/L and 0.250 ϫ 10 9 cells/L. We used these outcomes to produce incremental cost-effectiveness ratios; we used sensitivity analyses to examine the effect of key input parameters on the cost-effectiveness results.
CEPAC International Model
The CEPAC (Cost-Effectiveness of Preventing AIDS Complications) International model is a state-transition model of HIV disease in resource-limited settings, with data derived for several country-specific analyses, including South Africa (16, 20, 21) . In brief, a cohort of hypothetical patients pass one at a time through health states, in monthly cycles, from entry into HIV care until death. Health states are defined to be both clinically and economically relevant and are stratified by current CD4 count, current HIV RNA level, and history of opportunistic disease. Opportunistic diseases are categorized into the following groups on the basis of cause, severity, and similarities in prophylaxis and treatment: mild or The payoffs in terms of both clinical outcomes and costs are delineated to the right of the tree. The probability P represents the chance that the forthcoming trials studying ART initiation will demonstrate a clinical benefit of ART initiation at a CD4 count threshold of 0.350 ϫ 10 9 cells/L. Using a cost-effectiveness willingness-to-pay threshold of 3 times the per-capita gross domestic product of South Africa ($16 200/year of life saved), the tree suggests that initiating ART at CD4 counts less than 0.350 ϫ 10 9 cells/L now would be optimal for values of P such that $16 200
[outcomes (right branch)]}. As described in the Results section, values of P greater than 0.17 satisfy this decision rule. ART ϭ antiretroviral therapy.
severe bacterial infections, mild or severe fungal infections, tuberculosis, toxoplasmosis, nontuberculous mycobacteriosis, Pneumocystis jiroveci pneumonia, and other mild and severe diseases (5) . Deaths in the model occur from acute opportunistic events (within 30 days of the event), chronic AIDS (not within 30 days of an opportunistic disease), or non-HIVrelated causes (22) .
Effective ART in the model functions to suppress HIV RNA level and increase CD4 count (23, 24) . Beyond the beneficial effect of increased CD4 count on opportunistic diseases and chronic HIV-related death (5), ART results in an additional reduction in opportunistic diseases and chronic HIV-related death, as investigators in Côte d'Ivoire and the United States recently reported (25, 26) . Clinical assessments are assumed to occur every 3 months and CD4 and HIV RNA testing every 6 months while receiving therapy, consistent with South African recommendations (27) . In accordance with the current standard of care, the model uses 2 sequential lines of ART; the second line is initiated when observed CD4 count decreases by 30% from its peak observed on-treatment level or when a severe opportunistic disease is observed at least 6 months after initiation of therapy (27) . In accordance with current treatment guidelines, the second regimen for each patient is continued until death (7, 28) .
Input Parameters
Trial-Eligible Patients
For the short-term projections, we developed a hypothetical cohort of HIV-infected patients who had the appropriate clinical attributes ( Table 1) . We defined both a prevalent HIV-infected cohort (to indicate those currently infected) and an incident HIV-infected cohort (to indicate those who will become infected and trial-eligible during the 5-year horizon) (see Appendix 2, available at www. annals.org). We used previously described methods (16) to estimate the characteristics (CD4 count and viral load distribution) of the prevalent cohort in South Africa that might be eligible now at a CD4 count threshold for ART initiation of 0.350 ϫ 10 9 cells/L. The mean CD4 count was 0.321 ϫ 10 9 cells/L (SD, 0.146) for the prevalent cohort; 21% of patients in this cohort would be eligible for ART initiation at a threshold of 0.350 ϫ 10 9 cells/L versus 0.250 ϫ 10 9 cells/L. We also used projections from the Actuarial Society of South Africa to forecast the number of incident HIV infections anticipated over the 5-year trial horizon (29) . The incident cohort had a mean CD4 count of 0.534 ϫ 10 9 cells/L (SD, 0.164). In the first year after incident infection, 15% of patients in this cohort would be eligible for ART initiation at a threshold of 0.350 ϫ 10 9 cells/L versus 0.250 ϫ 10 9 cells/L. Because the CD4 counts and HIV RNA distributions of patients in the prevalent cohort and the incident cohorts differ, we derived survival data separately for each cohort. Using the CEPAC International model, we initialized the prevalent and incident cohorts to create a composite pic- Article When to Start Antiretroviral Therapy in Resource-Limited Settings ture of the CD4 and HIV RNA distribution of each cohort, given their duration of infection (16) . We projected the survival for HIV-infected patients who did not receive ART (for the no ART comparison) and those who began receiving ART at counts less than 0.350 ϫ 10 9 cells/L and less than 0.250 ϫ 10 9 cells/L (16). We calculated annual probabilities of survival (conditional on survival to the beginning of the year) by dividing the number of HIVinfected patients who were alive at the end of a given calendar year by the number who were alive at the end of the previous year. This reflects a patient's probability of surviving through the year, given that the patient was alive at the beginning of the year.
Cohort Characteristics
For the long-term projections, the simulated cohort was designed to resemble the characteristics of HIVinfected persons in South Africa. Clinical and demographic characteristics were based on data from the Cape Town AIDS Cohort (5). In the absence of specific data from South Africa, we obtained rates of CD4 count decrease, stratified by baseline HIV RNA level, from the Multicenter AIDS Cohort Study in the United States ( Table 1 ) (30) . We assumed that patients who entered the model were initiating HIV care and had a mean age of 32.8 years. For the long-term projections, we used a mean baseline CD4 count of 0.375 ϫ 10 9 cells/L to simulate enrollment criteria for the ART initiation trials; 42.5% of patients had baseline HIV RNA levels greater than 100 000 copies/mL ( Table 1) .
Opportunistic Disease Prophylaxis and Efficacy of Antiretroviral Therapy
In the absence of reported data from South Africa, we derived the efficacy of cotrimoxazole prophylaxis in our model from clinical trials in Côte d'Ivoire (31, 32) .
In Côte d'Ivoire, cotrimoxazole confers protection against bacterial infections, P. jiroveci pneumonia, isospora and malaria, and toxoplasmosis; isospora infection and malaria are not reported in the South African data ( Table 1 ) (20) . We assumed that 2 sequential antiretroviral regimens would be available. First-line therapy was a nonnucleoside reverse transcriptase inhibitor-based regimen with which a reported 84% of patients experienced HIV RNA suppression at 48 weeks (mean CD4 count increase, 0.184 ϫ 10 
Costs
We considered HIV-associated direct medical resource use, including inpatient days, outpatient visits, laboratory tests, and medication costs (19, (33) (34) (35) (36) (37) . We excluded direct nonmedical costs and indirect costs (such as patient time and lost wages). We used a utilization analysis and unit costing approach to derive health care use from the Cape Town AIDS cohort (5, 19, 33) . We derived costs on the basis of the number of inpatient hospital days and outpatient clinic visits associated with each type of opportunistic disease, or each month of routine HIV care in the absence of opportunistic disease, and the number of days and visits during the month of death.
Role of the Funding Source
The study was funded by the National Institute of Allergy and Infectious Diseases and the Doris Duke Foun- dation. The funding sources had no input in the study design, analysis and interpretation of data, writing of the report, or decision to submit for publication.
RESULTS
Outcomes Projected Over a 5-Year Horizon
We estimated that 4.7 million HIV-infected persons in South Africa would become eligible to start ART if the CD4 count threshold is 0.350 ϫ 10 9 cells/L instead of 0.250 ϫ 10 9 cells/L over a 5-year time horizon. Among such persons, 1.2 million are eligible now, 1.6 million will be eligible over the next year, and 1.9 million will become eligible over the ensuing 3 years.
For our assumptions that 10%, 30%, and 100% of these 4.7 million persons are identified and linked to care, we projected the opportunistic diseases, deaths, and costs over the next 5 years of alternative ART strategies while awaiting results of the ART initiation trials ( Table 2) cells/L would also lead to a discounted $142 million cost increase over the next 5 years, which reflects the additional treatment costs (offset in part by the reduced incidence of opportunistic diseases). At the maximum estimate (100% identification and linkage to care), 221 000 cases of opportunistic disease and 253 000 deaths could be averted. In this situation, the additional costs of using a threshold of 0.350 ϫ 10 9 cells/L would exceed $1.4 billion. Figure 2 provides results for the clinical and economic effect if between 10% and 100% of HIV-infected, eligible patients are identified and present for care. Clinical and cost results move together-the fewer patients identified, the fewer deaths and opportunistic diseases are averted and the lower the added total costs of an earlier ART initiation strategy.
Decision Criteria
We then examined the probability that the data from the forthcoming trials would provide enough statistical evidence that a CD4 count threshold for ART initiation of 0.350 ϫ 10 9 cells/L is superior to a 0.250 ϫ 10 9 cells/L threshold-which would confirm the model-based results. If this is certain (100% probability), the incremental costeffectiveness of a threshold of 0.350 ϫ 10 9 cells/L compared with 0.250 ϫ 10 9 cells/L is $2400/YLS, considering only the costs and benefits over the next 5 years. If the probability that the trials show a benefit to a threshold of 0.350 ϫ 10 9 cells/L decrease to 10%, the incremental costeffectiveness over the next 5 years would increase to $27 100/YLS. Using the established WHO cost-effectiveness guideline, a policy option to initiate ART at CD4 counts P represents the probability that the trial will confirm model-based results indicating a benefit of earlier therapy (see Methods and Figure 1) . The incremental cost-effectiveness is provided for the 5-year time horizon. The height of the bar provides the cost-effectiveness ratio of an initiation threshold of 0.350 ϫ 10 9 cells/L versus 0.250 ϫ 10 9 cells/L for alternative values of P; bars that remain below the horizontal solid line (Ͻ3 ϫ GDP) are considered to be cost-effective and those that remain below the horizontal dotted line (Ͻ1 ϫ GDP) are considered to be very cost-effective. ART ϭ antiretroviral therapy; GDP ϭ gross domestic product in South Africa (U.S. $5400); YLS ϭ year of life saved.
Article When to Start Antiretroviral Therapy in Resource-Limited Settings less than 0.350 ϫ 10 9 cells/L should be used over the next 5 years if the probability that the trial will confirm modelbased results is 17% or greater (Figure 3) . In sensitivity analyses, we varied the composite increase in deaths associated with an ART initiation threshold of 0.250 ϫ 10 
Lifetime Projections
When we projected long-term outcomes for a cohort with a mean CD4 count of 0.375 ϫ 10 9 cells/L, the notreatment strategy resulted in a mean survival of 3.83 years (4.11 undiscounted), compared with 11.71 years (15.23 undiscounted) at a CD4 count threshold for ART initiation of 0.250 ϫ 10 9 cells/L and 12.48 years (16.27 undiscounted) at a threshold of 0.350 ϫ 10 9 cells/L ( Table 3 ). The survival curves that corresponded to ART initiation thresholds of 0.350 ϫ 10 9 cells/L and 0.250 ϫ 10 9 cells/L diverged within about 1 year, after which time they became essentially parallel, when nearly all patients had initiated ART at a threshold of 0.250 ϫ 10 9 cells/L; by year 3, initiation at CD4 counts less than 0.350 ϫ 10 9 cells/L maintained a consistent 6% absolute advantage in the proportion of the cohort alive through year 10 (Figure 4) . Per-person lifetime direct costs were lowest with no ART ($3930) ( Table 3) Table 3) .
Sensitivity Analyses on Lifetime Projections
Because the long-term results consistently favored a CD4 count threshold for ART initiation of 0.350 ϫ 10 9 cells/L, we designed the sensitivity analyses to bias against earlier initiation. Specifically, we examined large decrements in second-line antiretroviral efficacy in the earlier therapy strategies. Second-line efficacy would have to be fewer than 39% of patients achieving HIV RNA suppression at 48 weeks-a 32% relative decrease from the base case-to match the projected survival rate from using a threshold of 0.250 ϫ 10 9 cells/L. To examine the effect of pill fatigue and failed retention in care (38, 39) , we also considered higher rates of discontinuation of care. We assumed that some patients who started ART at CD4 counts less than 0.350 ϫ 10 9 cells/L discontinued ART at the time they would have started receiving second-line regimens, thereby only realizing the benefits of first-line therapy (although they still received prophylaxis and treatment for opportunistic diseases). More than 19% of patients who received ART at a threshold of 0.350 ϫ 10 9 cells/L at the time of treatment failure would need to discontinue treatment to decrease survival to that associated with a threshold of 0.250 ϫ 10 9 cells/L. Finally, when we included a hypothetical third-line antiretroviral regimen, survival and costs increased for both ART treatment strategies. The incremental cost-effectiveness of using a threshold of 0.350 ϫ 10 9 cells/L was largely unchanged from that of using 0.250 ϫ 10 9 cells/L ($1000/YLS). Appendix 2 (available at www.annals.org) provides detailed results of these and other analyses.
DISCUSSION
Although the forthcoming trials in South Africa and other resource-limited settings should yield important information in the next 5 to 10 years, our analysis suggests that, until trial data are available, a CD4 count threshold of 0.350 ϫ 10 9 cells/L for initiating ART would probably yield better clinical outcomes than a lower threshold. The magnitude of such benefits multiply with increased rates of HIV identification and linkage to care. A threshold of 0.350 ϫ 10 9 cells/L is also expected to be highly costeffective in the interim. Many of the clinical benefits of starting earlier occur beyond the 5-year time horizon of the trial (manifested in increased life expectancy). Even so, our results suggest that a threshold of 0.350 ϫ 10 9 cells/L remains cost-effective if the probability is 17% or greater that the forthcoming trials will demonstrate improved clinical outcomes with starting ART earlier.
When ART is initiated according to current treatment guidelines, we found that an ART initiation threshold of 0.250 ϫ 10 9 cells/L is very cost-effective in the long term for HIV infection in South Africa, with a ratio of $1100/ YLS (7); for a threshold of 0.350 ϫ 10 9 cells/L, the costeffectiveness ratio is $1200/YLS. That these ratios are similar suggests that if HIV treatment is worth initiating, early initiation provides similar value to later treatment. We specifically designed sensitivity analyses to see how these results might change and found that very high rates of drug resistance and pill fatigue would be required to make earlier therapy not cost-effective. Because our results depend heavily on the frequency of opportunistic diseases at higher CD4 counts, morbidity rates should be assessed carefully at high CD4 counts; initiation of therapy at a greater CD4 count threshold than 0.350 ϫ 10 9 cells/L may be justified in South Africa.
Conducting the current trials remains critically important in informing the question of when to start ART. Evidence-based guidelines continue to maintain that randomized, controlled trials are the gold standard for developing policy; modeling analyses are still considered lower levels of evidence (40, 41). As such, randomized trials will probably be used as the benchmark evidence for HIV treatment throughout the world. Meanwhile, our model-based analysis suggests that opening up the option to start ART earlier in the disease course would probably improve clinical outcomes, at least until trial results are available. Our results suggest that 25 000 lives may be at stake; waiting 5 years for trial results could be costly in human terms.
Despite findings that a CD4 count threshold for ART initiation of 0.350 ϫ 10 9 cells/L may be beneficial, a study on patient characteristics at presentation to care in South Africa suggests that a discussion of earlier versus deferred ART initiation may not be germane at present; in that study, the mean CD4 count of patients who started ART was only 0.096 ϫ 10 9 cells/L (42). However, wider implementation of the WHO guidelines for using HIV testing technologies (43) and improved HIV screening and linkage to care should result in the identification of more patients who are eligible for earlier therapy initiation (7) . Decisions need to be made on how best to optimize their care, and efforts to identify them must continue if a policy of earlier therapy is to have a meaningful effect. Our analysis demonstrates that a CD4 count threshold of 0.350 ϫ 10 9 cells/L is highly effective and confers similar value to a threshold of 0.250 ϫ 10 9 cells/L. However, an ART initiation threshold of 0.350 ϫ 10 9 cells/L may not be optimal in some cases, such as when treatment capacity is limited-as is currently the case in many places (16) . In such settings, prioritization-whether ART should be provided on a first-come, first-served basis or on a CD4 count-based policy-is already problematic (44) . With inadequate treatment capacity, increasing the treatment initiation threshold for all patients to a CD4 count of 0.350 ϫ 10 9 cells/L, without prioritization for the sickest patients, could result in more deaths in the near term, even if earlier therapy is associated with long-term benefits. Thus, guidelines that move toward ART initiation at higher CD4 counts should be implemented only in settings with adequate capacity to treat all of those who are eligible and at highest risk.
Our study has limitations. First, this analysis does not represent an assessment of the estimated value of perfect information, which would examine whether the trial is worth doing. Because trials are already enrolling, we address the question of the optimal clinical strategy while awaiting the results of those trials. Second, we incorporated input data from multiple sources. Although they were uniformly derived, not all data are from similar cohorts in South Africa. Sensitivity analyses demonstrate that within reasonable reported ranges, our major conclusions are robust to these data estimates. Third, implementation of ART strategies by CD4 threshold in international settings-where CD4 testing is not universally availablemay require investments in infrastructure. Fourth, our model does not account for the potential benefits of ART, unrelated to opportunistic diseases, that might be attributable to treatment at CD4 thresholds higher than the cur- rent standard of care (45) . We also do not capture any additional benefits in preventing HIV transmission that earlier ART may confer because of viral load reduction (46). To the extent that these benefits occur, earlier therapy would be even more advantageous. Finally, earlier therapy may have other additional benefits in African countries that have higher rates of malaria and bacterial diseases than those documented in South Africa (5, 31) .
Ongoing randomized trials are studying the question of when to initiate ART in resource-limited settings. As these trials continue to enroll and accrue follow-up toward the primary outcomes, decisions must be made now regarding the optimal ART initiation policy in these settings. While we await trial results in settings of adequate treatment capacity, this study demonstrates that it is probably both effective and cost-effective to liberalize the opportunity for ART to be initiated at a CD4 count threshold of 0.350 ϫ 10 9 cells/L in South Africa.
